ABOUT SCORPION THERAPEUTICS

Recent advances in precision oncology approaches that target specific gene mutations have yielded personalized therapies, leading to improved prognosis for certain patients with cancer. However, there remains a significant unmet patient need primarily due to the majority of patients being ineligible for existing precision oncology therapies and certain patients that are currently eligible but experiencing a limited response or lack of durability due to limited selectivity and dose-limiting toxicities. As a result, despite the expansive development of precision oncology approaches in recent years, which represent approximately 70% of the more than 160 cancer drugs approved since 2001, it is estimated that only 14% of all patients with cancer are eligible for existing precision oncology therapies and only 7% see clinical benefits.

At Scorpion Therapeutics, we are focused on solving these gaps in treatment options for patients with cancer, which we call “therapeutic white spaces.” Our team comprises experienced and recognized leaders who have successfully discovered, developed, and commercialized therapies for various cancers at many of the leading pharmaceutical and biotech companies in the world. This collective expertise, combined with our platform of fully integrated drug discovery capabilities, enables us to address a wider array of targets through exquisitely selective small molecule compounds. We plan to efficiently progress these novel compounds through the discovery process and into clinical trials in well-defined patient populations, with the goal to ultimately deliver Precision Oncology 2.0 medicines.

Our goal, through Precision Oncology 2.0, is to transform the lives of patients with cancer by making safer and more effective precision therapeutic solutions available for all cancers.

< Back to Intro

Axel Hoos, M.D., Ph.D.

Chief Executive Officer

Dr. Axel Hoos is a distinguished physician-scientist, executive, entrepreneur and leader who became the CEO of Scorpion Therapeutics in August 2021. Prior to Scorpion Therapeutics, he served as Senior Vice President, R&D Governance Chair and Therapeutic Area Head for oncology at GlaxoSmithKline Pharmaceuticals (GSK).

Read more

Andrew Fedder

General Counsel

Andrew Fedder brings over a decade of legal experience to Scorpion Therapeutics. During the course of his career, he has advised on a wide array of complex business transactions in the pharmaceutical space, with a focus on acquisitions, divestitures and investments. Prior to joining Scorpion Therapeutics, Mr. Fedder worked at Bristol-Myers Squibb Company in increasing roles of responsibility, most recently acting as Assistant General Counsel for Corporate and Business Development and, previously, Senior Corporate Counsel for the company’s Mergers & Acquisitions team.

Read more

Adam Friedman, M.D., Ph.D.

President, Corporate Strategy & Business Development

Dr. Adam Friedman is an accomplished physician, scientist and life sciences entrepreneur with extensive experience in oncology. He currently serves as President, Corporate Strategy & Business Development, which follows his former role as interim CEO of Scorpion Therapeutics. Prior to joining the company, Dr. Friedman served as Director at Serien Therapeutics, a next-generation immuno-metabolism company.

Read more

Angel Guzman-Perez, Ph.D.

Head of Drug Discovery

Dr. Angel Guzman-Perez is the head of drug discovery at Scorpion Therapeutics, bringing extensive medicinal chemistry, drug discovery, and leadership experience. Prior to joining Scorpion Therapeutics, Dr. Guzman-Perez held leadership roles in Amgen’s research organization, serving as Executive Director, Head of Medicinal Chemistry and was responsible for the small-molecule portfolio across therapeutic areas.

Read more

Erica L. Jackson, Ph.D.

Executive Vice President, Target Biology

Dr. Erica L. Jackson has spent the past 20 years leading teams and mentoring scientists in oncology target validation and large and small molecule drug discovery. Prior to joining Scorpion Therapeutics, Dr. Jackson was Senior Director of Oncology Discovery at AbbVie, where she led a cross-site team of biologists responsible for all biology aspects of drug discovery from target ID through candidate nomination.

Read more

Brian Piper

Chief Financial Officer

Brian Piper brings more than 25 years of experience in corporate healthcare finance and has a successful track-record guiding biotechnology companies through significant organizational growth. Prior to joining Scorpion Therapeutics, he served as Chief Financial Officer at Prelude Therapeutics, where he established the finance function and helped lead the company to a successful initial public offering in 2020.

Read more

Kristin Schuhwerk

Chief Operating Officer

Kristin Schuhwerk brings over 25 years of leadership experience in pharmaceutical and biotechnology operations strategy and drug development, with particular expertise in project and portfolio management and clinical operations. Prior to joining Scorpion Therapeutics, Ms. Schuhwerk worked at Sanofi, where she served most recently as Vice President and Global Head of Project & Portfolio Management, Development, with responsibility for overall management and delivery of the company’s development portfolio.

Read more

Darrin Stuart, Ph.D.

Chief Scientific Officer

Dr. Darrin Stuart has spent the last 20 years leading and mentoring teams in small molecule drug discovery in the oncology therapeutic area. Dr. Stuart is the Chief Scientific Officer at Scorpion Therapeutics. Prior to joining Scorpion Therapeutics, Dr. Stuart was Executive Director of Cancer Biology and Drug Discovery at Novartis where he oversaw the oncology small molecule portfolio at the Cambridge, Mass. site.

Read more

Amanda Valentino

Chief People Officer

Amanda Valentino brings two decades of experience and leadership in talent acquisition, human resources and employee experience in the pharma/biotech industry. Prior to joining Scorpion Therapeutics, Ms. Valentino served as the Chief People Officer of Ambys Medicines, where she was responsible for designing the company’s approach to hiring and retaining talent.

Read more

Liron Bar-Peled, Ph.D.

Assistant Professor of Medicine, Harvard Medical School

Dr. Liron Bar-Peled is an Assistant Professor of Medicine at Harvard Medical School and the Cancer Center at Massachusetts General Hospital. His research focuses on deciphering fundamental mechanisms of stress signaling in cancer states and employing chemical proteomic platforms to discover new therapies for cancer.

Read more

Keith Flaherty, M.D.

Professor of Medicine, Harvard Medical School

Dr. Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. As described in the more than 300 peer-reviewed primary research reports he has authored or co-authored, Dr. Flaherty and colleagues made several seminal observations…

Read more

Gaddy Getz, Ph.D.

Professor of Medicine, Harvard Medical School Member, Broad Institute of MIT and Harvard

Dr. Gaddy Getz is an internationally acclaimed leader in cancer genomics and is pioneering widely used tools for analyzing cancer genomes. Dr. Getz is an institute member of the Broad Institute of MIT and Harvard, where he directs the Cancer Genome Computational Analysis Group. Dr. Getz is a Professor of Pathology at Harvard Medical School, and he is a faculty member and Director of Bioinformatics at the Massachusetts General Hospital (MGH) Cancer Center and Department of Pathology.

Read more

Gary Glick, Ph.D.

Co-Founder

Dr. Gary Glick co-founded Scorpion Therapeutics. Gary started his career as a faculty member at the University of Michigan in Ann Arbor, where he is currently the Werner E. Bachmann emeritus professor of chemistry. While at Michigan, Gary founded Lycera Corp. to develop new therapies for inflammation and cancer based on small molecules that modulate cellular metabolism.

Read more

Shelley Chu, M.D., Ph.D.

Director
LSVP, Head of Biotech

Keith Flaherty, M.D.

Director
Harvard Medical School

Jean-François Formela, M.D.

Director
Atlas Venture

Arjun Goyal, M.D., M.PHIL, M.B.A.

Director
Vida Ventures

Axel Hoos, M.D., Ph.D.

Director
CEO, Scorpion Therapeutics

Oleg Nodelman

Director
EcoR1

Otello Stampacchia

Director
Omega Funds

Aaron Davis

Observer
Boxer Capital

Meredith Fisher, Ph.D.

Observer
Mass General Brigham Ventures

Tim Haines

Observer
Abingworth

Annie Mitsak, Ph.D.

Observer
Omega Funds

Chelsea Place Johnson, Ph.D.

Observer
Atlas Venture

William Sellers, M.D.

Observer
Broad Institute
< Back to Intro

Investors